12049652

2 known cases. View patent page →

Cases
2
Active
2
0 closed
Filed
2025
Top venue
D. New Jersey
1 case

Halozyme, Inc. v. Merck Sharp & Dohme Corp. et al.

pending
Docket:
2:25-cv-03179-ES
Filed:
2025-04-24
Patents:12049652

Patent infringement and declaratory judgment action filed by Halozyme against Merck in the District of New Jersey asserting 15 Halozyme MDASE platform patents, including US 12,049,652, over subcutaneous pembrolizumab (Keytruda Qlex/Keytruda SC). The case remains pending and the '652 patent remains at issue.